Dataset Information

One-step radiosynthesis of the MCTs imaging agent [¹⁸F]FACH by aliphatic ¹⁸F-labelling of a methylsulfonate precursor containing an unprotected carboxylic acid group.

ABSTRACT: Monocarboxylate transporters 1 and 4 (MCT1 and MCT4) are involved in tumour development and progression. Their level of expression is particularly upregulated in glycolytic cancer cells and accordingly MCTs are considered as promising drug targets for treatment of a variety of human cancers. The non-invasive imaging of these transporters in cancer patients via positron emission tomography (PET) is regarded to be valuable for the monitoring of therapeutic effects of MCT inhibitors. Recently, we developed the first ¹⁸F-radiolabelled MCT1/MCT4 inhibitor [¹⁸F]FACH and reported on a two-step one-pot radiosynthesis procedure. We herein describe now a unique one-step radiosynthesis of this radiotracer which is based on the approach of using a methylsulfonate (mesylate) precursor bearing an unprotected carboxylic acid function. With the new procedure unexpected high radiochemical yields of 43?±?8% at the end of the radiosynthesis could be obtained in a strongly reduced total synthesis time. Moreover, the radiosynthesis was successfully transferred to a TRACERlab FX2 N synthesis module ready for future preclinical applications of [¹⁸F]FACH.

SUBMITTER: Sadeghzadeh M

PROVIDER: S-EPMC6906299 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

One-step radiosynthesis of the MCTs imaging agent [<sup>18</sup>F]FACH by aliphatic <sup>18</sup>F-labelling of a methylsulfonate precursor containing an unprotected carboxylic acid group.

Sadeghzadeh Masoud M Moldovan Rareş-Petru RP Teodoro Rodrigo R Brust Peter P Wenzel Barbara B

Scientific reports 20191211 1

Monocarboxylate transporters 1 and 4 (MCT1 and MCT4) are involved in tumour development and progression. Their level of expression is particularly upregulated in glycolytic cancer cells and accordingly MCTs are considered as promising drug targets for treatment of a variety of human cancers. The non-invasive imaging of these transporters in cancer patients via positron emission tomography (PET) is regarded to be valuable for the monitoring of therapeutic effects of MCT inhibitors. Recently, we d ...[more]

PMID: 31827199

Similar Datasets

Project description:BackgroundCurrent automated radiosynthesizers are generally optimized for producing large batches of PET tracers. Preclinical imaging studies, however, often require only a small portion of a regular batch, which cannot be economically produced on a conventional synthesizer. Alternative approaches are desired to produce small to moderate batches to reduce cost and the amount of reagents and radioisotope needed to produce PET tracers with high molar activity. In this work we describe the first reported microvolume method for production of [18F]Florbetaben for use in imaging of Alzheimer's disease.ProceduresThe microscale synthesis of [18F]Florbetaben was adapted from conventional-scale synthesis methods. Aqueous [18F]fluoride was azeotropically dried with K2CO3/K222 (275/383 nmol) complex prior to radiofluorination of the Boc-protected precursor (80 nmol) in 10 μL DMSO at 130 °C for 5 min. The resulting intermediate was deprotected with HCl at 90 °C for 3 min and recovered from the chip in aqueous acetonitrile solution. The crude product was purified via analytical scale HPLC and the collected fraction reformulated via solid-phase extraction using a miniature C18 cartridge.ResultsStarting with 270 ± 100 MBq (n = 3) of [18F]Fluoride, the method affords formulated product with 49 ± 3% (decay-corrected) yield,> 98% radiochemical purity and a molar activity of 338 ± 55 GBq/μmol. The miniature C18 cartridge enables efficient elution with only 150 μL of ethanol which is diluted to a final volume of 1.0 mL, thus providing a sufficient concentration for in vivo imaging. The whole procedure can be completed in 55 min.ConclusionsThis work describes an efficient and reliable procedure to produce [18F]Florbetaben in quantities sufficient for large-scale preclinical applications. This method provides very high yields and molar activities compared to reported literature methods. This method can be applied to higher starting activities with special consideration given to automation and radiolysis prevention.

Dataset Information

One-step radiosynthesis of the MCTs imaging agent [¹⁸F]FACH by aliphatic ¹⁸F-labelling of a methylsulfonate precursor containing an unprotected carboxylic acid group.

Publications

One-step radiosynthesis of the MCTs imaging agent [<sup>18</sup>F]FACH by aliphatic <sup>18</sup>F-labelling of a methylsulfonate precursor containing an unprotected carboxylic acid group.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

One-step radiosynthesis of the MCTs imaging agent [18F]FACH by aliphatic 18F-labelling of a methylsulfonate precursor containing an unprotected carboxylic acid group.

Publications

One-step radiosynthesis of the MCTs imaging agent [<sup>18</sup>F]FACH by aliphatic <sup>18</sup>F-labelling of a methylsulfonate precursor containing an unprotected carboxylic acid group.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

One-step radiosynthesis of the MCTs imaging agent [¹⁸F]FACH by aliphatic ¹⁸F-labelling of a methylsulfonate precursor containing an unprotected carboxylic acid group.